Regeneron, Sanofi's Dupixent Approved for COPD in China

Regeneron Pharmaceuticals and Sanofi received significant news as the NMPA approved Dupixent for treating adults with COPD in China, indicating a positive development for both companies and the healthcare landscape in the region.

Date: 27-09-2024

AI Rating: 7

The report highlights key information regarding the approval of Dupixent by the National Medical Products Administration (NMPA) in China for adults suffering from uncontrolled chronic obstructive pulmonary disease (COPD). This approval is based on data from the BOREAS and NOTUS Phase 3 studies, demonstrating that Dupixent significantly reduced exacerbations and improved lung function when compared to a placebo, indicating a positive outcome in terms of effectiveness.

Additionally, improvements in health-related quality of life post-treatment were noted, which is a crucial factor for potential users of Dupixent in the market. The approval comes at a time when COPD is recognized as the most prevalent chronic respiratory disease in China and aligns with the government’s Healthy China 2030 initiative aimed at addressing public health issues.

Furthermore, Dupixent has already been approved in over 30 countries globally, including all 27 countries in the European Union, demonstrating credibility and acceptance within the international medical community. The broad acceptance of Dupixent suggests that it could potentially generate significant revenue and profitability for Regeneron and Sanofi, enhancing both companies' market positions.

Stocks: REGN SNY